aXichem Notes a Continued Positive Trend for aXivite, Confirmed by New Orders from Uriach and Pharmafoods
Börskollen - Aktier, fonder och ekonominyheter

Börskollen

För dig med koll på börsen

Pressmeddelande

aXichem Notes a Continued Positive Trend for aXivite, Confirmed by New Orders from Uriach and Pharmafoods

aXichem AB (publ), a pioneer in the development and marketing of natural analogue industrial chemicals, is pleased to announce a new order for aXivite® under the agreement with Uriach, the renowned and expanding European pharmaceutical company. The order is related to the production of a new melatonin formula for Uriach’s brand Aquilea® featuring aXivite®. This means that the total order value from Uriach under the agreement to date, amounts to about 150,000 Euro.

aXichem has also received an order for aXivite from its Spanish distributor Pharmafoods at a value of 13,700 Euro for development of a new consumer product to be launched later this year.

We are pleased with the way our collaboration with Uriach evolves and are looking forward to seeing the Aquilea product with aXivite hitting the market. It is also very encouraging to see the activity in the Spanish market and to receive a new order from Pharmafoods. I believe that phenylcapsaicin's role as an active ingredient is significant and aXivite’s market potential in health and wellness will continue to tell its own story”, says Torsten Helsing, CEO of aXichem.

About phenylcapsaicin and aXivite
aXichem's proprietary molecule, phenylcapsaicin, combines the naturally occurring phenyl group with capsaicin, connected by a triple bond. The result is an innovative natural analog capsaicin with high purity, which in several studies has been shown to have the same health-promoting properties, as well as some unique benefits, as natural capsaicin. Phenylcapsaicin is approved under Novel Food in the EU and GRAS Food in the USA and is marketed for dietary supplements and functional foods under the brand name aXivite.

The information was submitted, through the care of the contact person below, for publication on 24 April 2024, at 10:00 CET.

Company contact:
Torsten Helsing, CEO, aXichem AB
Phone: +46 706 863 355 Email: [email protected]

About aXichem
aXichem develops, patents and markets natural analogue industrial chemicals, i.e., synthetically produced substances that have similar and comparable properties to natural substances. The company's first product is phenylcapsaicin, which the company commercializes under two brands, aXiphen® and aXivite®, as an ingredient in animal feed and dietary supplements, respectively. The business is divided into three market areas with different applications for phenylcapsaicin: as an ingredient in feed for poultry, such as chicken and turkey; as an ingredient in food supplements for gut health, weight control and sports and exercise; and as an ingredient in food supplements for the bio- enhancement of curcumin and melatonin. aXichem is listed on the Nasdaq First North Growth Market. Certified advisor for aXichem is Västra Hamnen Corporate Finance AB.

More information is available at www.axichem.com.

Bifogade filer

aXichem Notes a Continued Positive Trend for aXivite, Confirmed by New Orders from Uriach and Pharmafoodshttps://mb.cision.com/Main/8586/3966616/2754248.pdf

Nyheter om aXichem

Läses av andra just nu

Om aktien aXichem

Senaste nytt